321 related articles for article (PubMed ID: 31639439)
1. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.
Sanders MA; Haynes B; Nangia-Makker P; Polin LA; Shekhar MP
J Biol Chem; 2017 Jun; 292(25):10347-10363. PubMed ID: 28490629
[TBL] [Abstract][Full Text] [Related]
3. Nano-delivery of
Saadat N; Liu F; Haynes B; Nangia-Makker P; Bao X; Li J; Polin LA; Gupta S; Mao G; Shekhar MP
Mol Cancer Ther; 2018 Dec; 17(12):2586-2597. PubMed ID: 30242094
[TBL] [Abstract][Full Text] [Related]
4. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
5. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization.
Haynes B; Zhang Y; Liu F; Li J; Petit S; Kothayer H; Bao X; Westwell AD; Mao G; Shekhar MPV
Nanomedicine; 2016 Apr; 12(3):745-757. PubMed ID: 26563438
[TBL] [Abstract][Full Text] [Related]
6. CtIP mediates replication fork recovery in a FANCD2-regulated manner.
Yeo JE; Lee EH; Hendrickson EA; Sobeck A
Hum Mol Genet; 2014 Jul; 23(14):3695-705. PubMed ID: 24556218
[TBL] [Abstract][Full Text] [Related]
7. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
8. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells.
Gajan A; Sarma A; Kim S; Gurdziel K; Wu GS; Shekhar MP
Front Oncol; 2021; 11():694793. PubMed ID: 34367977
[TBL] [Abstract][Full Text] [Related]
10. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization.
Sanders MA; Brahemi G; Nangia-Makker P; Balan V; Morelli M; Kothayer H; Westwell AD; Shekhar MPV
Mol Cancer Ther; 2013 Apr; 12(4):373-83. PubMed ID: 23339190
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
12. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
[TBL] [Abstract][Full Text] [Related]
13. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
[TBL] [Abstract][Full Text] [Related]
14. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Jacquemont C; Taniguchi T
Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
[TBL] [Abstract][Full Text] [Related]
15. A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin.
Inoue A; Kikuchi S; Hishiki A; Shao Y; Heath R; Evison BJ; Actis M; Canman CE; Hashimoto H; Fujii N
J Biol Chem; 2014 Mar; 289(10):7109-7120. PubMed ID: 24474685
[TBL] [Abstract][Full Text] [Related]
16. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
Teraoka S; Muguruma M; Takano N; Miyahara K; Kawate T; Kaise H; Yamada K; Miyazawa K; Ishikawa T
J Surg Res; 2020 Jun; 250():200-208. PubMed ID: 32092597
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance.
Haynes B; Saadat N; Myung B; Shekhar MP
Mutat Res Rev Mutat Res; 2015; 763():258-66. PubMed ID: 25795124
[TBL] [Abstract][Full Text] [Related]
19. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]